Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 124,632
  • Shares Outstanding, K 10,580
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,330 K
  • 60-Month Beta 1.55
  • Price/Sales 2,077.20
  • Price/Cash Flow N/A
  • Price/Book 15.31
Trade ANVS with:

Options Overview Details

View History
  • Implied Volatility 266.63% ( +2.88%)
  • Historical Volatility 101.35%
  • IV Percentile 57%
  • IV Rank 34.71%
  • IV High 472.50% on 12/13/23
  • IV Low 157.17% on 12/20/23
  • Put/Call Vol Ratio 1.72
  • Today's Volume 2,835
  • Volume Avg (30-Day) 1,569
  • Put/Call OI Ratio 1.59
  • Today's Open Interest 36,536
  • Open Int (30-Day) 26,590

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.35
  • Number of Estimates 2
  • High Estimate -1.06
  • Low Estimate -1.63
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -255.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.10 +48.52%
on 02/29/24
13.26 -9.28%
on 03/20/24
+2.24 (+22.88%)
since 02/27/24
3-Month
8.10 +48.52%
on 02/29/24
21.50 -44.04%
on 12/28/23
-7.59 (-38.69%)
since 12/27/23
52-Week
5.42 +121.96%
on 11/08/23
23.89 -49.64%
on 03/29/23
-6.82 (-36.18%)
since 03/27/23

Most Recent Stories

More News
S&P Futures Tick Lower as Investors Await Key U.S. GDP Data and Fed Speak

March S&P 500 E-Mini futures (ESH24) are trending down -0.27% this morning as market participants looked ahead to a new round of U.S. economic data, comments from Fed officials, and earnings reports from...

ESH24 : 5,101.67s (-1.01%)
NCLH : 21.34 (+5.85%)
CEG : 184.89 (-0.28%)
ZM : 66.62 (+0.41%)
WDAY : 273.62 (-1.36%)
U : 26.99 (+1.09%)
CRM : 301.38 (-1.46%)
TJX : 101.08 (+1.79%)
SNOW : 160.04 (+1.28%)
HPQ : 30.12 (+0.43%)
ASM.NA : 576.800 (+0.51%)
RKT.LN : 4,502.000 (+1.44%)
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and...

ANVS : 12.03 (+2.12%)
Wall Street Analysts See a 213.78% Upside in Annovis Bio, Inc. (ANVS): Can the Stock Really Move This High?

The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 213.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

ANVS : 12.03 (+2.12%)
Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs

Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.

BIIB : 216.34 (+2.04%)
RHHBY : 31.3100 (unch)
ANVS : 12.03 (+2.12%)
CELU : 4.94 (-1.79%)
Best Momentum Stocks to Buy for April 21st

ANVS, ACLX and WOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 21, 2023.

WOR : 61.96 (+2.36%)
ANVS : 12.03 (+2.12%)
ACLX : 70.45 (+0.46%)
New Strong Buy Stocks for April 21st

WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.

WOR : 61.96 (+2.36%)
SIEGY : 96.2400 (+1.70%)
RYI : 32.91 (+2.84%)
ANVS : 12.03 (+2.12%)
ACLX : 70.45 (+0.46%)
ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases is...

ANVS : 12.03 (+2.12%)
ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases,...

ANVS : 12.03 (+2.12%)
New Strong Buy Stocks for April 18th

EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.

ANDE : 57.32 (+1.45%)
HCC : 62.07 (+4.37%)
MPC : 196.99 (-0.20%)
EGY : 6.87 (+1.63%)
ANVS : 12.03 (+2.12%)
ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases,...

ANVS : 12.03 (+2.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 13.07
2nd Resistance Point 12.68
1st Resistance Point 12.36
Last Price 12.03
1st Support Level 11.65
2nd Support Level 11.26
3rd Support Level 10.94

See More

52-Week High 23.89
Fibonacci 61.8% 16.83
Fibonacci 50% 14.65
Fibonacci 38.2% 12.47
Last Price 12.03
52-Week Low 5.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar